Format

Send to

Choose Destination
Womens Health (Lond). 2016 Jun;12(3):379-88. doi: 10.2217/whe-2016-0001. Epub 2016 Feb 29.

Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes.

Author information

1
University of California, Irvine, CA, USA.
2
Kushner Wellness Center, 3745 Long Beach Blvd, Suite 100, Long Beach, CA 90807, USA.

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as canagliflozin, are used in patients with Type 2 diabetes mellitus (T2DM). In clinical studies, canagliflozin significantly reduced A1C, bodyweight and blood pressure, and was generally well tolerated with no increased risk of hypoglycemia. Most common adverse effects observed were genital mycotic infections and urinary tract infections, and increased urination. Approximately 10% of women treated with canagliflozin experienced a genital mycotic infection compared with 3% treated with placebo; those with a prior history were at greater risk. Approximately 9% of women treated with canagliflozin reported a urinary tract infection compared with 7% treated with placebo. Most adverse events were considered mild to moderate in intensity and responded to standard therapy. Treatment with canagliflozin was effective and generally well tolerated in both women (and men) with T2DM.

KEYWORDS:

SGLT2; T2DM; canagliflozin; efficacy; safety; women's health

PMID:
26928259
PMCID:
PMC5384506
DOI:
10.2217/whe-2016-0001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center